Mumbai, April 21,2018: Pharma Major, Cipla Ltd ssaid that US Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) audit at Company’s Indore formulations facility from April 2, 2018 till April 13, 2018.
This was in the normal course of business. There were no data integrity and or repeat observations.
The company believes the observations are unlikely to have any material adverse impact and it will submit the response within the stipulated timeframe.
United News of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…